AstraZeneca stated that its COVID-19 vaccine was 76% effective in preventing symptomatic illness in a new analysis of its major U.S. trial. This is a bit lower than the level of 79% announced earlier in a report that was criticized for having outdated information.

The latest data come from 190 infections among over 32,400 participants in the trial conducted in United States, Chile and Peru. The earlier data from an interim analysis was based on 141 infections through February 17. The company further stated on Thursday that the vaccine was 100% effective against severe or critical disease, and had 85% efficacy in adults aged 65 years and above.

The company now intends to seek U.S. emergency use authorization in the following weeks… (Reuters, March 25, 2021)